Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12150259 | 0.79 | MAPKAPK2 (0.41) | — | |
| SCHEMBL13537185 | 0.79 | RPS6KB1 (0.42) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL13537188 | 0.79 | ROCK1 (0.44) | HDAC4HDAC7HDAC5ROCK2ROCK1 | |
| SCHEMBL13537191 | 0.78 | HDAC4 (0.40) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL13537184 | 0.78 | HDAC4 (0.46) | HDAC4HDAC7HDAC5MTORCES2 | |
| SCHEMBL15247594 | 0.76 | HDAC4 (0.50) | HDAC4HDAC7HDAC5MTORCES2 | |
| SCHEMBL10087244 | 0.76 | HDAC4 (0.46) | HDAC4HDAC7HDAC5MTORCES2 | |
| SCHEMBL17614064 | 0.76 | HDAC4 (0.46) | HDAC4HDAC7HDAC5MTORCES2 | |
| SCHEMBL16168343 | 0.76 | HDAC4 (0.46) | HDAC4HDAC7HDAC5MTORCES2 | |
| SCHEMBL22365056 | 0.74 | HDAC4 (0.44) | HDAC4HDAC7HDAC5MTORCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | HDAC4 1277/4885HDAC7 1367/4885HDAC5 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.